SCHEMBL9909016

SCHEMBL9909016

CC1(C)[C@@H]2C(=O)N(Cc3ccccc3)C(=O)[C@@H]21

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 4/20 0.59
MEN1 O00255 2/20 0.59
KMT2A Q03164 2/20 0.59
ALDH1A1 P00352 4/20 0.54
ACHE P22303 1/20 0.54
CTSG P08311 2/20 0.53
F2 P00734 1/20 0.53
PLG P00747 1/20 0.53
CMA1 P23946 1/20 0.53
CTRC Q99895 1/20 0.53
TSHR P16473 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
PRTN3 P24158 1/20 0.51
EP300 Q09472 1/20 0.50
GSK3A P49840 1/20 0.50
GSK3B P49841 1/20 0.50
MGLL Q99685 1/20 0.50
NPSR1 Q6W5P4 1/20 0.49
ADRA2A P08913 1/20 0.46
NISCH Q9Y2I1 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12469648 1.00 ELANE (0.59) ELANEMEN1KMT2AALDH1A1ACHE
SCHEMBL6620106 0.80 ELANE (0.53) ELANEMEN1KMT2AALDH1A1CTSG
SCHEMBL6742469 0.79 ELANE (0.56) ELANEMEN1KMT2AALDH1A1CTSG
SCHEMBL14189455 0.79 ELANE (0.56) ELANEMEN1KMT2AALDH1A1CTSG
SCHEMBL9975770 0.79 KMT2A (0.66) ELANEMEN1KMT2AALDH1A1CTSG
SCHEMBL10031595 0.79 KMT2A (0.66) ELANEMEN1KMT2AALDH1A1CTSG
SCHEMBL22025234 0.78 ACHE (0.61) ELANEMEN1KMT2AALDH1A1ACHE
SCHEMBL1190997 0.78 ACHE (0.68) ELANEMEN1KMT2AALDH1A1ACHE
SCHEMBL16759895 0.78 KMT2A (0.70) ELANEMEN1KMT2AALDH1A1CTSG
SCHEMBL16775234 0.78 KMT2A (0.70) ELANEMEN1KMT2AALDH1A1CTSG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110734384-B Preparation method of hydroxyamide 南方科技大学 2022-09-20 CN disclosed
EP-1963267-B1 PROCESS FOR THE PREPARATION OF 6, 6-DIMETHYL-3-AZABICYCLO-[3.1.0]-HEXANE COMPOUNDS AND ENANTIOMERIC SALTS THEREOF MERCK SHARP & DOHME (US) 2013-08-14 EP disclosed
US-8198463-B2 Process for the preparation of 6,6-dimethyl-3-azabicyclo-[3.3.0]-hexane compounds and enantiomeric salts thereof SCHERING CORPORATION (US) 2012-06-12 US disclosed
US-8158807-B2 Process for the preparation of 6,6-dimethyl-3-azabicyclo-[3.1.0]-hexane compounds utilizing bisulfite intermediate SCHERING CORPORATION (US) 2012-04-17 US disclosed
US-20110092716-A1 DEHYDROHALOGENATION PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL IN PROVIDING 6,6-DIMETHYL-3-AZABICYCLO-[3.1.0]- HEXANE COMPOUNDS KWOK DAW-LONG 2011-04-21 US disclosed
US-20110092716-A1 DEHYDROHALOGENATION PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL IN PROVIDING 6,6-DIMETHYL-3-AZABICYCLO-[3.1.0]- HEXANE COMPOUNDS KWOK DAW-LONG 2011-04-21 US disclosed
US-20100256393-A1 PROCESS FOR THE PREPARATION OF 6,6- DIMETHYL-3-AZABICYCLO-[3.1.0]-HEXANE COMPOUNDS AND ENANTIOMERIC SALTS THEREOF SCHERING CORPORATION (US) 2010-10-07 US disclosed
US-20100145069-A1 PROCESS FOR THE PREPARATION OF 6,6-DIMETHYL-3-AZABICYCLO-[3.1.0]- HEXANE COMPOUNDS UTILIZING BISULFITE INTERMEDIATE SCHERING CORPORATION (US) 2010-06-10 US disclosed
US-7723531-B2 Process for the preparation of 6,6-dimethyl-3-azabicyclo-[3.1.0]-hexane compounds and enantiomeric salts thereof SCHERING CORPORATION (US) 2010-05-25 US disclosed
US-7723531-B2 Process for the preparation of 6,6-dimethyl-3-azabicyclo-[3.1.0]-hexane compounds and enantiomeric salts thereof SCHERING CORPORATION (US) 2010-05-25 US disclosed
US-20090240063-A1 Process For The Preparation Of 6,6-Dimethyl-3-Azabicyclo-[3.1.0]-Hexane Compounds ... MERCK SHARP & DOHME CORP. 2009-09-24 US disclosed
US-20090240063-A1 Process For The Preparation Of 6,6-Dimethyl-3-Azabicyclo-[3.1.0]-Hexane Compounds ... MERCK SHARP & DOHME CORP. 2009-09-24 US disclosed
WO-2007075790-A1 PROCESS FOR THE PREPARATION OF 6, 6-DIMETHYL-3-AZABICYCLO-[3.1.0]-HEXANE COMPOUNDS AND ENANTIOMERIC SALTS THEREOF SCHERING CORPORATION (US) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110092716-A1 DEHYDROHALOGENATION PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL IN PROVIDING 6,6-DIMETHYL-3-AZABICYCLO-[3.1.0]- HEXANE COMPOUNDS CYP1B1, CYP2B6, CYP2D6 ELANE 4825/4885MEN1 2699/4885KMT2A 1738/4885
US-20100256393-A1 PROCESS FOR THE PREPARATION OF 6,6- DIMETHYL-3-AZABICYCLO-[3.1.0]-HEXANE COMPOUNDS AND ENANTIOMERIC SALTS THEREOF TMT1A, HDHD5, DLST ELANE 4757/4885MEN1 4086/4885KMT2A 55/4885
US-20100145069-A1 PROCESS FOR THE PREPARATION OF 6,6-DIMETHYL-3-AZABICYCLO-[3.1.0]- HEXANE COMPOUNDS UTILIZING BISULFITE INTERMEDIATE DNMT1, TET2, TET3 ELANE 4751/4885MEN1 2139/4885KMT2A 199/4885
US-20090240063-A1 Process For The Preparation Of 6,6-Dimethyl-3-Azabicyclo-[3.1.0]-Hexane Compounds ... TMT1A, HDHD5, TET1 ELANE 4722/4885MEN1 4365/4885KMT2A 28/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.